COMPASS THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
COMPASS THERAPEUTICS, INC. (CMPX) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $8.60 million for the 3-month period ending 2025-09-30, per its 10-K filed 2026-03-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-05
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-09-30 was $8.60M.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $500.00K, a 0.00% change year-over-year.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-03-31 was $500.00K.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-06-30 was $100.00K.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $500.00K.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $4.50M, a 47.06% decline from fiscal 2021.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2021 was $8.50M, a 34.92% increase from fiscal 2020.
- COMPASS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2020 was $6.30M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month as first filed | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|
| 2025-09-30 | $8.60M 10-K · filed 2026-03-05 | ||
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-08 | ||
| 2024-12-31 | $500.00K 10-K · filed 2025-02-27 | ||
| 2024-03-31 | $500.00K 10-K · filed 2026-03-05 | ||
| 2023-06-30 | $100.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $4.50M 10-K · filed 2023-03-15 | ||
| 2021-12-31 | $8.50M 10-K · filed 2023-03-15 | ||
| 2020-12-31 | $6.30M 10-K · filed 2022-03-18 | ||
| 2020-06-30 | $6.90M 10-Q · filed 2021-11-12 | $6.90K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |